

Title (en)
SULFOALKYL ETHER CYCLODEXTRIN BASED CONTROLLED RELEASE SOLID PHARMACEUTICAL FORMULATIONS

Title (de)
FESTE PHARMAZEUTISCHE FORMULIERUNGEN AUF BASIS VON SULFOALKYLETERN DES CYCLODEXTRINS ZUR VERZÖGERTEN FREISETZUNG

Title (fr)
FORMULATIONS PHARMACEUTIQUES SOLIDES A LIBERATION PROLONGEE A BASE D'ETHER SULFOALKYLE DE CYCLODEXTRINE

Publication
EP 1140960 A1 20011010 (EN)

Application
EP 00903234 A 20000111

Priority
• US 0000640 W 20000111
• US 22951399 A 19990113

Abstract (en)
[origin: US6046177A] Sulfoalkyl ether cyclodextrin (SAE-CD) based controlled release pharmaceutical formulations are provided by the present invention. The present solid pharmaceutical formulations consist of a core comprising a physical mixture of one or more SAE-CD derivatives, an optional release rate modifier, a therapeutic agent, a major portion of which is not complexed to the SAE-CD, and an optional release rate modifying coating surrounding the core. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative is used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents. Multi-layered, osmotic pump, coated, and uncoated tablet, minitab, pellet, micropellet, particle, powder, and granule dosage forms are disclosed herein.

IPC 1-7
C07H 13/12; C08B 37/16

IPC 8 full level
A61K 9/22 (2006.01); **A61K 9/00** (2006.01); **A61K 9/16** (2006.01); **A61K 9/20** (2006.01); **A61K 9/24** (2006.01); **A61K 9/26** (2006.01); **A61K 9/28** (2006.01); **A61K 9/32** (2006.01); **A61K 9/50** (2006.01); **A61K 9/52** (2006.01); **A61K 9/54** (2006.01); **A61K 9/58** (2006.01); **A61K 31/573** (2006.01); **A61K 47/40** (2006.01); **A61P 5/40** (2006.01); **C08B 37/16** (2006.01)

CPC (source: EP KR US)
A61K 9/20 (2013.01 - KR); **A61K 9/205** (2013.01 - EP US); **A61K 9/2059** (2013.01 - EP US); **A61K 9/209** (2013.01 - EP US); **A61K 9/2826** (2013.01 - EP US); **A61K 9/2846** (2013.01 - EP US); **A61K 9/2853** (2013.01 - EP US); **A61K 9/2866** (2013.01 - EP US); **A61K 9/4808** (2013.01 - EP US); **A61K 47/40** (2013.01 - EP US); **A61K 47/6951** (2017.07 - EP US); **A61P 5/40** (2017.12 - EP); **B82Y 5/00** (2013.01 - EP US)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
US 6046177 A 20000404; AT E374017 T1 20071015; AU 2501100 A 20000801; AU 758376 B2 20030320; CA 2360236 A1 20000720; CA 2360236 C 20090428; CN 1202833 C 20050525; CN 1370072 A 20020918; DE 60036534 D1 20071108; DE 60036534 T2 20090129; EP 1140960 A1 20011010; EP 1140960 A4 20030326; EP 1140960 B1 20070926; EP 1859790 A2 20071128; EP 1859790 A3 20080305; EP 1897559 A1 20080312; EP 1897560 A1 20080312; ES 2290012 T3 20080216; HK 1049797 A1 20030530; IL 143900 A0 20020421; IL 143900 A 20081126; JP 2002534472 A 20021015; JP 2006316076 A 20061124; KR 100712941 B1 20070502; KR 20010101481 A 20011114; KR 20050092056 A 20050916; MX PA01007122 A 20030721; NZ 512692 A 20021025; PT 1140960 E 20071129; RU 2233176 C2 20040727; RU 2233176 C9 20060210; WO 0041704 A1 20000720

DOCDB simple family (application)
US 22951399 A 19990113; AT 00903234 T 20000111; AU 2501100 A 20000111; CA 2360236 A 20000111; CN 00802747 A 20000111; DE 60036534 T 20000111; EP 00903234 A 20000111; EP 07017925 A 20000111; EP 07017926 A 20000111; EP 07017927 A 20000111; ES 00903234 T 20000111; HK 03101970 A 20030318; IL 14390000 A 20000111; IL 14390001 A 20010621; JP 2000593314 A 20000111; JP 2006239768 A 20060905; KR 20017008810 A 20010712; KR 20057015530 A 20050823; MX PA01007122 A 20000111; NZ 51269200 A 20000111; PT 00903234 T 20000111; RU 2001119270 A 20000111; US 0000640 W 20000111